Tetrahydropalmatine has been shown to have analgesic effects and may benefit research into heart disease and liver damage. It is a voltage-activated l-type calcium and potassium channel blocker. It has also shown potential in the treatment of addiction to cocaine and opioid compounds, and preliminary human studies have shown promising results. THP treatment significantly increased the activity of key MyoD activating myotropin kinases p38MAPK and Akt. THP treatment restored myoduct formation in C2C12-deficient cells by activating p38MAPK. THP enhanced myOd-mediated transformation and differentiation of 10T1/2 fibroblasts into myoblasts. Tetrahydropalmatine may have a potential research candidate to prevent fibrosis and improve muscle regeneration and repair.
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
SPH3127 is an oral direct renin inhibitor (DRI) that is being developed for hypertension. The renin-angiotensin-aldosterone system is responsible for the regulation of blood pressure.
SAfit2 is a potent inhibitor of FK506-binding protein 51 (FKBP51) with a Ki value of 6 nM. SAfit2 has been used as a potential agent in the study of major depression, obesity, and chronic pain.
“lipid 10a” (Arcturus tunable lipid for RNA drug delivery).
BAY 1214784 is a potent, selective and orally active antagonist of the human gonadotropin-releasing hormone receptor (hGnRH-R).BAY 1214784 has the potential to be studied in uterine fibroids.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.